<DOC>
	<DOCNO>NCT00101374</DOCNO>
	<brief_summary>This study evaluate effect leflunomide life cycle specific immune cell call CD4+ T cell HIV-infected patient . Leflunomide approve Food Drug Administration treat rheumatoid arthritis . It work block cell division activate T cell . In HIV infection , HIV virus cause increase activation T cell . The activated cell become infected die . Activation may also cause death T cell infect HIV . T cell necessary body fight infection cancer . This study see leflunomide block T-cell division possibly reduce number cell die , reduce number cell HIV reproduce , lead low level HIV virus body . HIV-infected patient 18 65 year age 1 ) HIV viral level 1,000 copies/mL , 2 ) CD4+ T-cell count 350 cells/mm3 , 3 ) CD4+ T-cell count never less 200 cells/mm3 may eligible study . Candidates screen medical history , physical examination , blood urine test , chest x-ray , electrocardiogram ( EKG ) . Participants randomly assign take leflunomide placebo ( substance active ingredient ) every day 28 day . They come clinic three time first 29 day study ( day 1 , 15 , 29 ) physical examination review drug side effect . Patients take placebo end participation day 29 . Patients take leflunomide stop take drug day 29 begin take cholestyramine three time day 11 day next 14 day clear leflunomide body . On day 43 , return clinic leflunomide level check make sure little none drug remain body . If level low , patient end participation around day 57 . If level remain high , repeat cholestyramine treatment .</brief_summary>
	<brief_title>Effect Leflunomide T Cell Proliferation HIV-Infected Patients</brief_title>
	<detailed_description>Increased T cell turnover one main abnormality observe HIV infect patient one main mechanism lead CD4 lymphopenia . This lead hypothesis medication act directly suppress immune activation normalize T cell turnover , could use HIV infection . The purpose protocol evaluate effect immunomodulatory agent , leflunomide , CD4+ T cell proliferation HIV infect adult . HIV infect adult stable HIV viral load take antiretrovirals receive leflunomide placebo 28 day . CD4+ T cell proliferation measure percent Ki67 expression , change expression baseline day 28 compare group . Various study measure immune parameter CD4+ CD8+ T cell count level activation collect well safety study HIV viral load . The primary study risk adverse reaction leflunomide . The study double-blinded randomize 2:1 ( leflunomide versus placebo ) review DSMB . Total enrollment study 18 patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>INCLUSION CRITERIA : Age great equal 18 less equal 65 year . HIV infect . CD4+ cell count great equal 350 cells/mm ( 3 ) screen historical nadir ( since diagnosis HIV ) great equal 200 cells/mm ( 3 ) . Plasma HIV viral load great equal 1,000 copies/mL screening . Ability understand sign inform consent willingness comply study requirement clinic policy . Must primary care physician take care patient HIV infection . Female study subject reproductive potential ( defined girl reach menarche woman postmenopausal least 24 consecutive month , i.e. , menses within precede 24 month undergone sterilization procedure ( hysterectomy bilateral oophorectomy ) , must negative serum urine pregnancy test . Agreement participate conception process ( eg . active attempt become pregnant impregnate , sperm donation , vitro fertilization ) follow strict contraceptive measure study . If participate sexual activity could lead pregnancy , study volunteer must agree two reliable method contraception use simultaneously entire study . Acceptable form contraception include : Condoms ( male female ) without spermicidal agent . Condoms recommend appropriate use contraception method effective prevent HIV transmission . Diaphragm cervical cap spermicide . IUD . Hormonalbased contraception . Study subject reproductive potential ( woman postmenopausal least 24 consecutive month , woman undergo hysterectomy bilateral oophorectomy , prepubescent boy men document azoospermia ) eligible without require use contraception . Written oral documentation communicate clinician clinician 's staff one following : Physician report/letter . Operative report source documentation patient record ( laboratory report azoospermia require document successful vasectomy ) . Discharge summary . Laboratory report azoospermia . FSH measurement elevate menopausal range establish report laboratory . EXCLUSION CRITERIA : Current treatment antiretrovirals use antiretrovirals within 12 week screen . Intention start antiretroviral regimen within 64 day study period . Previous treatment leflunomide . Previous treatment IL2 . Treatment immunomodulatory agent ( include hydroxyurea , mycophenolate , cyclosporine , rapamycin , antiHIV vaccine , interleukin IL2 , interferon ) within 60 day study . Treatment systemic corticosteroid within 30 day study . Inability unwillingness discontinue drug ( except NSAIDS ) metabolize P450 2C9 isoenzyme ( see Appendix A Medications Metabolized CYP 2C9 Contraindicated During Treatment Period ) . Inability unwillingness discontinue hepatotoxic drug ( eg . isoniazid , rifampin , HMG CoA reductase inhibitor ) . Inability unwillingness discontinue drug interact cholestyramine ( eg . diminish absorption cholestyramine ) ( see Appendix B Medications Interactions Cholestyramine ) . Current use know intolerance cholestyramine bile acid sequestering resin . History familial hyperlipoproteinemia type III , IV V. Active bacterial infection within 4 week screen . History AIDSdefining illness ( category C ) ( see Appendix C CDC AIDS Classification Criteria ) . Hepatitis B C infection . Acute chronic liver disease cause ( eg . alcoholic hepatitis alcohol induce cirrhosis , autoimmune hepatitis , primary biliary cirrhosis , sclerosing cholangitis , Wilson 's disease , hemochromatosis ) investigator feel would compromise subject 's safety . History biliary obstruction . Current alcohol abuse unwillingness abstain alcohol use study period . History hypertension control ( less 140/80 mm/Hg ) single antihypertensive agent . Abnormal laboratory finding : hemoglobin le 10 g/dL ; ANC le 1000/mm ( 3 ) ; platelet le 100,000/mm ( 3 ) ; creatine upper limit normal ; ALT alkaline phosphatase great 1.25 time upper limit normal ; AST great 1.25 time upper limit normal ( subject isolate AST elevation , high normal CPK value absence liver disease compatible history intense exercise allow rescreen study investigator suspect elevate AST muscular origin ) direct bilirubin great 1.5 time upper limit normal ; total bilirubin great 2 time upper limit normal lipase great 1.5 time upper limit normal ; PT great 1.1 time upper limit normal ; PTT great 1.5 time upper limit normal . History malignant neoplasm except situ anogenital carcinoma , adequately treat basal squamous cell carcinoma skin solid tumor treat curative therapy disease free least five year . Significant medical psychiatric disorder investigator feel would interfere subject 's ability participate would compromise safety . Women currently pregnant breastfeeding . History interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2, 2010</verification_date>
	<keyword>Immunomodulatory Drug</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Ki67+</keyword>
	<keyword>Immune Activation</keyword>
	<keyword>T Cell Proliferation</keyword>
	<keyword>HIV</keyword>
	<keyword>Activated CD4+T-cell</keyword>
	<keyword>Proliferation</keyword>
</DOC>